Jazz Selling General Administrative from 2010 to 2024

JAZZ Stock  USD 111.22  1.76  1.61%   
Jazz Pharmaceuticals Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative is likely to outpace its year average in 2024. During the period from 2010 to 2024, Jazz Pharmaceuticals Selling General Administrative regression line of annual values had r-squared of  0.92 and arithmetic mean of  698,167,980. View All Fundamentals
 
Selling General Administrative  
First Reported
2005-12-31
Previous Quarter
308.3 M
Current Value
396 M
Quarterly Volatility
116.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz main balance sheet or income statement drivers, such as Interest Expense of 368.7 M, Other Operating Expenses of 3.3 B or Operating Income of 692.2 M, as well as many exotic indicators such as Price To Sales Ratio of 1.93, Dividend Yield of 0.0107 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Jazz Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Jazz Pharmaceuticals Technical models . Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Jazz Pharmaceuticals PLC over the last few years. It is Jazz Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Jazz Selling General Administrative Regression Statistics

Arithmetic Mean698,167,980
Geometric Mean510,385,048
Coefficient Of Variation69.89
Mean Deviation399,717,176
Median544,142,000
Standard Deviation487,984,405
Sample Variance238128.8T
Range1.4B
R-Value0.96
Mean Square Error20717.4T
R-Squared0.92
Slope104,616,246
Total Sum of Squares3333802.9T

Jazz Selling General Administrative History

20241.4 B
20231.3 B
20221.4 B
20211.5 B
2020854.2 M
2019736.9 M
2018683.5 M

About Jazz Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Jazz Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Jazz Pharmaceuticals investors use historical funamental indicators, such as Jazz Pharmaceuticals's Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Jazz Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Jazz Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Jazz Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Jazz Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative1.3 B1.4 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.
Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Jazz Stock analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
CEOs Directory
Screen CEOs from public companies around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.757
Earnings Share
6.1
Revenue Per Share
60.581
Quarterly Revenue Growth
0.041
Return On Assets
0.0456
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.